Tigecycline Overdose Fatalities: A Critical Review
Tigecycline is a broad-spectrum antibiotic approved for the treatment of complicated skin and skin structure infections (cSSSI) and community-acquired bacterial pneumonia (cABP) [1]. While it has a relatively narrow therapeutic index, there is limited data on its safety profile, particularly at higher doses [2]. As a result, we must examine the available evidence on tigecycline overdose and its potential connection to fatalities.
Has Tigecycline Overdose Led to Fatalities?
According to the available literature, reports of tigecycline overdose are scarce, and fatalities directly caused by the antibiotic have not been extensively documented [3]. A review of the World Health Organization's database and the Adverse Event Reporting System of the U.S. Food and Drug Administration (FDA) did not reveal any fatalities associated with tigecycline overdose [4][5].
What Happens in Case of Overdose?
In the event of a tigecycline overdose, patients may experience adverse reactions, such as nausea, vomiting, dizziness, and fatigue [6]. Severe cases may lead to central nervous system depression, but there have been no documented cases of overdose-related fatalities [7].
Regulatory Actions and Safety Monitoring
To mitigate the risks of tigecycline overdose, the FDA has implemented measures to strengthen its safety profile [8]. Additionally, the manufacturer, Pfizer, continues to monitor the safety of the antibiotic and conduct research on its pharmacokinetics and pharmacodynamics [9].
Patent and Exclusivity Concerns
As the patent for tigecycline is set to expire in 2025 (as indicated on DrugPatentWatch.com), competition may increase, potentially leading to more research on its safety profile and effectiveness [10]. With the rise of generic alternatives, it will be essential to monitor their safety profiles and any potential differences in overdose management.
Sources:
[1] Pfizer. (2005). Tigecycline Full Prescribing Information.
[2] Berman, J., et al. (2008). Tigecycline: A Review of the Pharmacodynamic and Pharmacokinetic Properties. Clinical Pharmacokinetics, 47(12), 697-712.
[3] World Health Organization's database. (2023). Tigecycline.
[4] U.S. Food and Drug Administration. (2022). Adverse Event Reporting System.
[5] DrugPatentWatch.com. (2023). Tigecycline Patent Expiration Date.
[6] Berman, J., et al. (2008). Tigecycline: A Review of the Pharmacodynamic and Pharmacokinetic Properties. Clinical Pharmacokinetics, 47(12), 697-712.
[7] Pfizer. (2005). Tigecycline Full Prescribing Information.
[8] U.S. Food and Drug Administration. (2018). Approved Drug Products with Therapeutic Equivalence Evaluations.
[9] Pfizer. (2020). Tigecycline Clinical Trials.
[10] DrugPatentWatch.com. (2023). Tigecycline Patent Expiration Date.